Patent US350897A successfully refreshed from Google Patents.
Patent US3962423A successfully refreshed from Google Patents.
US3962423A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Live influenza type B virus vaccines and preparation thereof
Assignee: Recherche et Industrie Therapeutiques
•
Filing: 1975-04-18
•
Granted: 1976-06-08
•
Expires: 1995-04-18
Abstract
Abstract Attenuated stable influenza type B virus strains are obtained by recombining a vaccinal and previously attenuated influenza type B virus strain with an influenza type B virus isolate having the desired serotype and isolating a recombinant having at least one marker property of the attenuated parent strain which is not shared by the other parent strain and the antigenic composition of the other parent strain. The obtained strains are useful for the production of nasal influenza vaccines.
Inventors
- 👤 Julien Peetermans
- 👤 Michele Lobmann
- 👤 Jean-Marie Prevost
- 👤 Emil Vascoboinic
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-08 12:07
CPC Classifications
A; A61; A61K; A61K39/00; A61K39/12; A61K39/145; A61K2039/51; A61K2039/525; A61K2039/5254; A61K2039/54; A61K2039/541; A61K2039/543; A61K2039/70; C; C12; C12N; C12N2760/00; C12N2760/00011; C12N2760/16011; C12N2760/16111; C12N2760/16134; C12N2760/16211; C12N2760/16234
Claims Analysis
Total Claims: 13
Claim 1
Independent Claim
94 words
A live influenza virus vaccine effective on intranasal administration comprising an effective amount of an attenuated influenza type B virus recombinant strain obtained by recombining a first vaccinal attenuated influenza type B virus strain resistant to serum inhibitors with a second influenza type B virus strain, and isolating a recombinant having (1) at least one marker property of the said first virus strain selected from the group consisting of positive allantoic membrane on shell and resistance to serum inhibitors and (2) the antigenic characteristics of the said second virus strain, and a carrier therefor.
Claim 2
Dependent Claim
94 words
A live influenza virus vaccine effective on intranasal administration comprising an effective amount of an attenuated influenza type B virus recombinant strain obtained by recombining a first vaccinal attenuated influenza type B virus strain resistant to serum inhibitors with a second influenza type B virus strain, and isolating a recombinant having (1) at least one marker property of the said first virus strain selected from the group consisting of positive allantoic membrane on shell and resistance to serum inhibitors and (2) the antigenic characteristics of the said second virus strain, and a carrier therefor.
Claim 3
Dependent Claim
32 words
A live influenza virus vaccine according to claim 1, wherein the first vaccinal attenuated influenza type B virus strain resistant to serum inhibitors is influenza type B Brigit strain (ATCC VR 786).
Claim 4
Dependent Claim
21 words
A vaccine according to claim 2, wherein the second virus strain is influenza type B strain B/Hong Kong/5/72 (ATCC VR 791).
Claim 5
Dependent Claim
17 words
A vaccine according to claim 3, wherein the recombinant is influenza type B strain (ATCC VR 788).
Claim 6
Dependent Claim
17 words
A vaccine according to claim 3, wherein the recombinant is influenza type B strain (ATCC VR 789).
Claim 7
Dependent Claim
21 words
A vaccine according to claim 2, wherein the second virus strain is influenza type B strain B/Hong Kong/8/73 (ATCC VR 792).
Claim 8
Dependent Claim
17 words
A vaccine according to claim 6, wherein the recombinant is influenza type B strain (ATCC VR 787).
Claim 9
Dependent Claim
32 words
A live influenza virus vaccine effective on intranasal administration comprising a vaccine according to claim 1 and an effective amount of an attenuated influenza type A virus vaccine effective on intranasal administration.
Claim 10
Dependent Claim
23 words
A vaccine according to claim 8, wherein the attenuated influenza type A virus is influenza type A virus Alice strain (ATCC VR 776).
Claim 11
Dependent Claim
17 words
A vaccine according to claim 7, wherein the influenza type B strain recombinant is ATCC VR 789.
Claim 12
Dependent Claim
21 words
A vaccine according to claim 1, wherein the effective amount of the recombinant is at least 10 7 EID 50 .
Claim 13
Dependent Claim
13 words
A vaccine according to claim 1, in which peptone is present as stabilizer.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1979-06-08 | 1979-12-08 | 1980-06-08 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1983-06-08 | 1983-12-08 | 1984-06-08 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1987-06-08 | 1987-12-08 | 1988-06-08 | $7700.00 | Window Closed / Lapsed |